Literature DB >> 33868660

Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat.

Renumathy Dhanasekaran1, Paul Y Kwo1.   

Abstract

Entities:  

Year:  2021        PMID： 33868660      PMCID： PMC8043713          DOI： 10.1002/cld.1003

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  10 in total

1.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

Authors:  María Reig; Zoe Mariño; Christie Perelló; Mercedes Iñarrairaegui; Andrea Ribeiro; Sabela Lens; Alba Díaz; Ramón Vilana; Anna Darnell; María Varela; Bruno Sangro; José Luis Calleja; Xavier Forns; Jordi Bruix
Journal:  J Hepatol       Date:  2016-04-13       Impact factor: 25.083

2.  Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.

Authors:  Stacey B Prenner; Lisa B VanWagner; Steven L Flamm; Riad Salem; Robert J Lewandowski; Laura Kulik
Journal:  J Hepatol       Date:  2017-02-02       Impact factor: 25.083

3.  Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease.

Authors:  Lisa I Backus; Pamela S Belperio; Troy A Shahoumian; Larry A Mole
Journal:  Hepatology       Date:  2018-05-15       Impact factor: 17.425

4.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.

Authors:  Fasiha Kanwal; Jennifer Kramer; Steven M Asch; Maneerat Chayanupatkul; Yumei Cao; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2017-06-19       Impact factor: 22.682

5.  Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.

Authors:  Pierre Nahon; Richard Layese; Valérie Bourcier; Carole Cagnot; Patrick Marcellin; Dominique Guyader; Stanislas Pol; Dominique Larrey; Victor De Lédinghen; Denis Ouzan; Fabien Zoulim; Dominique Roulot; Albert Tran; Jean-Pierre Bronowicki; Jean-Pierre Zarski; Ghassan Riachi; Paul Calès; Jean-Marie Péron; Laurent Alric; Marc Bourlière; Philippe Mathurin; Jean-Frédéric Blanc; Armand Abergel; Lawrence Serfaty; Ariane Mallat; Jean-Didier Grangé; Pierre Attali; Yannick Bacq; Claire Wartelle; Thông Dao; Dominique Thabut; Christophe Pilette; Christine Silvain; Christos Christidis; Eric Nguyen-Khac; Brigitte Bernard-Chabert; David Zucman; Vincent Di Martino; Angela Sutton; Françoise Roudot-Thoraval; Etienne Audureau
Journal:  Gastroenterology       Date:  2018-07-19       Impact factor: 22.682

6.  Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.

Authors:  Amit G Singal; Nicole E Rich; Neil Mehta; Andrea D Branch; Anjana Pillai; Maarouf Hoteit; Michael Volk; Mobolaji Odewole; Steven Scaglione; Jennifer Guy; Adnan Said; Jordan J Feld; Binu V John; Catherine Frenette; Parvez Mantry; Amol S Rangnekar; Omobonike Oloruntoba; Michael Leise; Janice H Jou; Kalyan Ram Bhamidimarri; Laura Kulik; George N Ioannou; Annsa Huang; Tram Tran; Hrishikesh Samant; Renumathy Dhanasekaran; Andres Duarte-Rojo; Reena Salgia; Sheila Eswaran; Prasun Jalal; Avegail Flores; Sanjaya K Satapathy; Sofia Kagan; Purva Gopal; Robert Wong; Neehar D Parikh; Caitlin C Murphy
Journal:  Gastroenterology       Date:  2019-07-30       Impact factor: 22.682

7.  Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.

Authors:  Fabio Conti; Federica Buonfiglioli; Alessandra Scuteri; Cristina Crespi; Luigi Bolondi; Paolo Caraceni; Francesco Giuseppe Foschi; Marco Lenzi; Giuseppe Mazzella; Gabriella Verucchi; Pietro Andreone; Stefano Brillanti
Journal:  J Hepatol       Date:  2016-06-24       Impact factor: 25.083

Review 8.  Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer.

Authors:  David R McGivern; Stanley M Lemon
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

9.  Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Jordi Bruix; Tadatoshi Takayama; Vincenzo Mazzaferro; Gar-Yang Chau; Jiamei Yang; Masatoshi Kudo; Jianqiang Cai; Ronnie T Poon; Kwang-Hyub Han; Won Young Tak; Han Chu Lee; Tianqiang Song; Sasan Roayaie; Luigi Bolondi; Kwan Sik Lee; Masatoshi Makuuchi; Fabricio Souza; Marie-Aude Le Berre; Gerold Meinhardt; Josep M Llovet
Journal:  Lancet Oncol       Date:  2015-09-08       Impact factor: 41.316

10.  HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.

Authors:  George N Ioannou; Pamela K Green; Kristin Berry
Journal:  J Hepatol       Date:  2017-09-05       Impact factor: 25.083
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.